KYNB — Kyntra Bio Cashflow Statement
0.000.00%
Last trade - 00:00- $28.37m
- -$6.54m
- $6.44m
Annual cashflow statement for Kyntra Bio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -290 | -294 | -284 | -47.6 | 183 |
| Depreciation | |||||
| Non-Cash Items | 133 | 66.7 | 76.7 | 22.1 | -39.9 |
| Unusual Items | |||||
| Purchased R&D | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 60.1 | 70.4 | -117 | -115 | -149 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -82.2 | -146 | -315 | -138 | -4.77 |
| Capital Expenditures | -30.2 | -38.7 | -2.52 | -0.266 | -0.038 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -397 | 128 | 156 | 126 | 35.5 |
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -427 | 89.1 | 154 | 126 | 35.4 |
| Financing Cash Flow Items | -7.37 | -6.62 | -0.237 | -0.354 | -5.47 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -0.563 | 46.8 | 123 | -0.255 | -86 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -507 | -15.5 | -42 | -11.5 | -54.3 |